Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 11-12/2015

01.06.2015 | original article

Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream

verfasst von: MD, PhD Helga Sertić Milić, PhD Ana Franjević, PhD Gordana Bubanović, MD, PhD Ante Marušić, MD, PhD Igor Nikolić, MD, PhD Igor Puljić

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

The computed tomography (CT) is the “golden standard” for the assessment of lung cancer progression due to its ability to clearly display the radiomorphologic characteristics. As lung cancer mortality is very high, more comprehensive approaches may be needed for its earlier diagnosis. The research hypothesis was to investigate the relation between the CT morphologic characteristics (size, stage, and edges) of pulmonary lesion and the extent of release of a soluble fragment of cytokeratin 19 being a part of the cytoskeleton of lung epithelial cells.

Methods

This is a retrospective study including 246 pulmonary lesions being diagnosed and subsequently treated at the University Hospital Centre Zagreb, Croatia. The information about the relevant clinical, radiological, and laboratory facts was collected at the time of diagnosis in 164 NSCLC patients, 52 patients with pulmonary metastases, and 30 benign cysts. CYFRA 21-1 was determined by electrochemiluminescence immunoassay. The nonparametric statistical methods were applied.

Results

There was a positive correlation between the size and CYFRA 21-1 in NSCLC unlike metastases or cysts (p = 0.0001). The highest values of CYFRA 21-1 were seen in advanced stages of NSCLC and lesions with spiculated edges.

Conclusions

The level of CYFRA 21-1 positively correlates with the greatest size of NSCLC measured by CT. The differences in CYFRA 21-1 according to TNM classification are significant (p = 0.0001): higher values were observed in advanced stages and with tumors having spiculated, lobulated, and poorly defined edges. The combination of CYFRA 21-1 and CT may help articulate the malignancy of pulmonary lesions.
Literatur
3.
Zurück zum Zitat Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. Thorac Surg Clin. 2004;14:1–13. PubMedCrossRef Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. Thorac Surg Clin. 2004;14:1–13. PubMedCrossRef
4.
Zurück zum Zitat Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. Eur Respir J Suppl. 2002;35:40S–8S. PubMedCrossRef Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. Eur Respir J Suppl. 2002;35:40S–8S. PubMedCrossRef
5.
Zurück zum Zitat Schafer-Prokop C, Prokop M. New imaging techniques in the treatment guidelines for lung cancer. Eur Respir J. 2002;35(Suppl.):71S–83S. Schafer-Prokop C, Prokop M. New imaging techniques in the treatment guidelines for lung cancer. Eur Respir J. 2002;35(Suppl.):71S–83S.
6.
Zurück zum Zitat Verschakelen JA, De Wever W, Bogaert J, Stroobant S. Imaging: staging of lung cancer. Eur Respir Monogr. 2004;30:214–44. Verschakelen JA, De Wever W, Bogaert J, Stroobant S. Imaging: staging of lung cancer. Eur Respir Monogr. 2004;30:214–44.
7.
Zurück zum Zitat Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of current evidence. Chest. 2003;123(1 Suppl.):137S–46S. PubMedCrossRef Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of current evidence. Chest. 2003;123(1 Suppl.):137S–46S. PubMedCrossRef
8.
Zurück zum Zitat Hyer JD, Silvestri G. Diagnosis and staging of lung cancer. Clin Chest Med. 2000;21:95–106. PubMedCrossRef Hyer JD, Silvestri G. Diagnosis and staging of lung cancer. Clin Chest Med. 2000;21:95–106. PubMedCrossRef
9.
Zurück zum Zitat Goldstraw P. The 7 th edition of TNM in lung cancer: what now? J Thoracic Oncol. 2009;4:671–3. CrossRef Goldstraw P. The 7 th edition of TNM in lung cancer: what now? J Thoracic Oncol. 2009;4:671–3. CrossRef
10.
Zurück zum Zitat Chen C, Bao F, Zheng H, Zhou YM, Bao MW, Xie HK, et al. Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. Ann Thorac Surg. 2012;93:389–96. PubMedCrossRef Chen C, Bao F, Zheng H, Zhou YM, Bao MW, Xie HK, et al. Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. Ann Thorac Surg. 2012;93:389–96. PubMedCrossRef
11.
Zurück zum Zitat Lee C, Byun C, Lee J, Kim D, Cho B, Chung K, et al. The prognostic factors of resected non-small cell lung cancer with chest wall invasion: a retrospective study. World J Surg Oncol. 2012;12:9. CrossRef Lee C, Byun C, Lee J, Kim D, Cho B, Chung K, et al. The prognostic factors of resected non-small cell lung cancer with chest wall invasion: a retrospective study. World J Surg Oncol. 2012;12:9. CrossRef
12.
Zurück zum Zitat Neralic Meniga I, Kujundzic Tiljak M, Ivankovic D, Aleric I, Zekan M, Hrabac P, et al. Prognostic value of computed tomography morphologic characteristics in stage I non-small cell lung cancer. Clin Lung Cancer. 2010;11:98–104. Neralic Meniga I, Kujundzic Tiljak M, Ivankovic D, Aleric I, Zekan M, Hrabac P, et al. Prognostic value of computed tomography morphologic characteristics in stage I non-small cell lung cancer. Clin Lung Cancer. 2010;11:98–104.
13.
Zurück zum Zitat Atance-León P, Moreno-Mata N, González-Aragoneses F, Canizares-Carretero MÁ, García-Jiménez MD, Genovés-Crespo M, et al. Multicenter analysis of survival and prognostic factors in pathologic stage I non-small cell lung cancer according to the new 2009 TNM classification. Arch Bronconeumol. 2011;47:441–6. Atance-León P, Moreno-Mata N, González-Aragoneses F, Canizares-Carretero MÁ, García-Jiménez MD, Genovés-Crespo M, et al. Multicenter analysis of survival and prognostic factors in pathologic stage I non-small cell lung cancer according to the new 2009 TNM classification. Arch Bronconeumol. 2011;47:441–6.
14.
Zurück zum Zitat Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57. PubMedCrossRef Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57. PubMedCrossRef
15.
Zurück zum Zitat Pujol JL, Boher JM, Grenier J, Quantin X. CYFRA 21-1, neuron-specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001;31:221–31. PubMedCrossRef Pujol JL, Boher JM, Grenier J, Quantin X. CYFRA 21-1, neuron-specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001;31:221–31. PubMedCrossRef
16.
Zurück zum Zitat Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol. 2003;24:209–18. CrossRef Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol. 2003;24:209–18. CrossRef
18.
Zurück zum Zitat Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest. 1992;102:1748–51. PubMedCrossRef Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest. 1992;102:1748–51. PubMedCrossRef
19.
20.
Zurück zum Zitat Moll R, Franke WW, Schiller D, Geiger B, Krepler R. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24. PubMedCrossRef Moll R, Franke WW, Schiller D, Geiger B, Krepler R. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24. PubMedCrossRef
22.
Zurück zum Zitat Aktogu S, Yuncu G, Halilcolar H, Ermete S, Buduneli T. Bronchogenic cysts: clinicopathological presentation and treatment. Eur Respir J. 1996;9:2017–21. PubMedCrossRef Aktogu S, Yuncu G, Halilcolar H, Ermete S, Buduneli T. Bronchogenic cysts: clinicopathological presentation and treatment. Eur Respir J. 1996;9:2017–21. PubMedCrossRef
23.
Zurück zum Zitat McAdams HP, Kirejczyk WM, Rosado-de-Christenson ML, Matsumoto S. Bronchogenic cyst: features with clinical and histopathologic correlation. Radiology. 2000;217:441–6. PubMedCrossRef McAdams HP, Kirejczyk WM, Rosado-de-Christenson ML, Matsumoto S. Bronchogenic cyst: features with clinical and histopathologic correlation. Radiology. 2000;217:441–6. PubMedCrossRef
Metadaten
Titel
Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream
verfasst von
MD, PhD Helga Sertić Milić
PhD Ana Franjević
PhD Gordana Bubanović
MD, PhD Ante Marušić
MD, PhD Igor Nikolić
MD, PhD Igor Puljić
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0678-2